Unlocking Sulforaphane's Potential: Evgen's CEO Shares 2016 Plans
This article was originally published in Scrip
Sulforaphane, a potential anticancer agent and neuroprotectant found in brassica vegetables, is the basis of newly listed Evgen Pharma's technology, Sulforadex. Evgen has created a synthetic version of the molecule with its technology, which it believes will be successful in treating types of cancer, multiple sclerosis (MS) and subarachnoid hemorrhage. Scrip's Lubna Ahmed spoke to Evgen's CEO Dr. Stephen Franklin to find out more about where the company started, its technology and what we should expect from Evgen moving into 2016.
Register for our free email digests: